| Jordan Paul Sand, MD | |
|
307 W 6th Ave Ste 200, Spokane, WA 99204-2502 | |
| (509) 324-2980 | |
| (094) 189-4625 |
| Full Name | Jordan Paul Sand |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 13 Years |
| Location | 307 W 6th Ave Ste 200, Spokane, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417243668 | NPI | - | NPPES |
| Entity Name | Columbia Surgical Specialists, Ps |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417067372 PECOS PAC ID: 2860305505 Enrollment ID: O20031110000300 |
News Archive
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that it has entered into an exclusive US $75 million license agreement with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of its PSA-activated pro-drug, PRX302, in Japan for BPH, prostate cancer and other diseases of the prostate. Protox retains exclusive rights to PRX302 in all other territories.
A study presented today at the IASLC 2021 World Conference on Lung Cancer suggests how oncology practices in the United States changed after 2018, when durvalumab became available for patients with unresectable Stage III non-small cell lung cancer.
Iron deficiency predicts lower IQ scores and poor higher-order thinking skills in children adopted from institutional settings like orphanages, according to a new longitudinal study.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.
The Advanced Wound Management Division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew Plc (LSE: SN; NYSE: SNN), announced today that clinicians will present a total of 20 clinical posters featuring its Negative Pressure Wound Therapy (NPWT) Systems and ALLEVYN(TM) AG, ALLEVYN AG Gentle, ACTICOAT(TM) and IODOSORB(TM) advanced wound dressings during the 24th Annual Clinical Symposium on Advances in Skin and Wound Care's poster session. The poster session opens at 10:30am CT on October 23, 2009.
› Verified 8 days ago
| Entity Name | Sand Plastic Surgery Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306518113 PECOS PAC ID: 2163803628 Enrollment ID: O20220715000810 |
News Archive
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that it has entered into an exclusive US $75 million license agreement with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of its PSA-activated pro-drug, PRX302, in Japan for BPH, prostate cancer and other diseases of the prostate. Protox retains exclusive rights to PRX302 in all other territories.
A study presented today at the IASLC 2021 World Conference on Lung Cancer suggests how oncology practices in the United States changed after 2018, when durvalumab became available for patients with unresectable Stage III non-small cell lung cancer.
Iron deficiency predicts lower IQ scores and poor higher-order thinking skills in children adopted from institutional settings like orphanages, according to a new longitudinal study.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.
The Advanced Wound Management Division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew Plc (LSE: SN; NYSE: SNN), announced today that clinicians will present a total of 20 clinical posters featuring its Negative Pressure Wound Therapy (NPWT) Systems and ALLEVYN(TM) AG, ALLEVYN AG Gentle, ACTICOAT(TM) and IODOSORB(TM) advanced wound dressings during the 24th Annual Clinical Symposium on Advances in Skin and Wound Care's poster session. The poster session opens at 10:30am CT on October 23, 2009.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jordan Paul Sand, MD 307 W 6th Ave Ste 200, Spokane, WA 99204-2502 Ph: (093) 242-9805 | Jordan Paul Sand, MD 307 W 6th Ave Ste 200, Spokane, WA 99204-2502 Ph: (509) 324-2980 |
News Archive
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that it has entered into an exclusive US $75 million license agreement with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of its PSA-activated pro-drug, PRX302, in Japan for BPH, prostate cancer and other diseases of the prostate. Protox retains exclusive rights to PRX302 in all other territories.
A study presented today at the IASLC 2021 World Conference on Lung Cancer suggests how oncology practices in the United States changed after 2018, when durvalumab became available for patients with unresectable Stage III non-small cell lung cancer.
Iron deficiency predicts lower IQ scores and poor higher-order thinking skills in children adopted from institutional settings like orphanages, according to a new longitudinal study.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.
The Advanced Wound Management Division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew Plc (LSE: SN; NYSE: SNN), announced today that clinicians will present a total of 20 clinical posters featuring its Negative Pressure Wound Therapy (NPWT) Systems and ALLEVYN(TM) AG, ALLEVYN AG Gentle, ACTICOAT(TM) and IODOSORB(TM) advanced wound dressings during the 24th Annual Clinical Symposium on Advances in Skin and Wound Care's poster session. The poster session opens at 10:30am CT on October 23, 2009.
› Verified 8 days ago
Shane A Zim, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 217 W Cataldo Ave, Spokane, WA 99201 Phone: 509-624-2326 Fax: 509-252-2837 | |
Michael Joseph Cruz, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 217 W Cataldo Ave Fl 2, Spokane, WA 99201 Phone: 509-624-2326 Fax: 509-744-3040 | |
Neil Arthur Giddings, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 217 W Cataldo, Spokane, WA 99201 Phone: 509-624-2326 Fax: 509-744-3040 | |
Jason D. Roos, D.O. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 801 W 5th Ave, Suite 205, Spokane, WA 99204 Phone: 509-838-2531 Fax: 509-755-6580 | |
John Finley Hoffmann, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 217 W Cataldo, Spokane, WA 99201 Phone: 509-624-2326 Fax: 509-744-3040 | |
Alan T Pokorny, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 217 W Cataldo Ave Fl 2, Spokane, WA 99201 Phone: 509-624-2326 Fax: 509-744-3040 |